FDA approves AbbVie's Juvmo (tavapadon) for Parkinson's, a D1/D5 agonist from its $8.7B Cerevel buy with fewer side effects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results